Zelira Therapeutics Limited

CHIA:ZLD Stock Report

Market Cap: AU$7.3m

Zelira Therapeutics Valuation

Is ZLD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZLD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZLD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZLD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZLD?

Key metric: As ZLD barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ZLD. This is calculated by dividing ZLD's market cap by their current book value.
What is ZLD's PB Ratio?
PB Ratio-1.6x
Book-AU$4.51m
Market CapAU$7.26m

Price to Book Ratio vs Peers

How does ZLD's PB Ratio compare to its peers?

The above table shows the PB ratio for ZLD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.8x
AVE Avecho Biotechnology
1.5xn/aAU$6.3m
EPN Epsilon Healthcare
0.8xn/aAU$7.2m
CGB Cann Global
0.5xn/aAU$5.4m
EOF Ecofibre
0.4xn/aAU$15.4m
ZLD Zelira Therapeutics
n/an/aAU$7.3m

Price-To-Book vs Peers: ZLD has negative equity and a Price-To-Book Ratio (-1.6x) compared to the peer average (0.9x).

Price to Book Ratio vs Industry

How does ZLD's PB Ratio compare vs other companies in the AU Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
LGP Little Green Pharma
0.5x110.1%US$25.49m
EOF Ecofibre
0.4xn/aUS$9.98m
CGB Cann Global
0.5xn/aUS$3.69m
No more companies available in this PB range
ZLD is unprofitableIndustry Avg. 4.1xNo. of Companies8PB02.85.68.411.214+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ZLD has negative equity and a Price-To-Book Ratio (-1.6x) compared to the Australian Pharmaceuticals industry average (4.1x).

Price to Book Ratio vs Fair Ratio

What is ZLD's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZLD PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio-1.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ZLD's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Neuren Pharmaceuticals

AU$1.6b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

NEU

AU$12.36

7D

-26.0%

1Y

-17.0%

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

7D

0%

1Y

10.2%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

7D

-5.6%

1Y

-46.8%